

## PRESS RELEASE

### AbbVie announces leadership changes for Australia



**SYDNEY, AUSTRALIA October 5, 2022** – AbbVie (NYSE: ABBV) today announced that Nathalie McNeil has been named Vice President and General Manager of AbbVie Australia & New Zealand, reporting to Alberto Colzi, Senior Vice President, Intercontinental.

Nathalie joined Allergan as Associate Vice President and General Manager for Australia & New Zealand in early 2019, prior to the integration with AbbVie.

Welcoming Nathalie to the role, Mr. Colzi said, “Nathalie is a greatly respected leader with a strong track-record of building high performing teams to achieve outstanding business results.

“She was instrumental in leading the Allergan Aesthetics organisational transformation in Australian and New Zealand, which has resulted in exceptional growth and set the organisation up for enduring success.

“Her commitment to equality, diversity & inclusion, and deep care and passion for her team is a hallmark of her leadership,” he said.

Nathalie has 25 years' experience in the healthcare and pharmaceutical industry, with a broad range of senior leadership experience across sales & marketing, business development and strategy, and human resources.

Nathalie's promotion coincides with Chris Stemple being named Regional Vice President, Europe, Region North reporting to Jerome Bouyer, Senior Vice President, Europe.

Chris joined AbbVie in 2020 as Vice President and General Manager of AbbVie Australia & New Zealand (ANZ), reporting to Alberto Colzi.

In congratulating Chris on his promotion, Mr. Colzi said, “Chris demonstrated exceptional leadership in guiding the Australian and New Zealand Affiliates through considerable commercial and organisational change, including the recent successful integration of Allergan.





“During this time the ANZ business has experienced significant growth and is considered a best-practice Affiliate for commercial excellence and innovative approaches to customer and patient experience.

“Chris is well known as a leader who is deeply committed to people focused strategy and this is demonstrated in the company’s recent achievement of ranking fifth place in the prestigious Great Place to Work Best Workplaces List.”

Chris has served as a Board member of Medicines Australia since 2019 and in this capacity was a Steering Committee member of the Pharma Australia Inclusion Group. In addition, Chris is a Pay Equity Ambassador with the Workplace Gender Equality Agency, with AbbVie holding an employer of choice citation with the same agency.

Coinciding with these leadership changes, Allergan Aesthetics announced Ellen Qiu has been appointed General Manager Allergan Aesthetics, ANZ. Ellen joined Allergan Aesthetics in 2020 as the Botox Area Brand Lead for JAPAC.

Before joining Allergan Aesthetics, Ellen held a variety of roles within the pharmaceutical industry in China. She has a BSc in Economics from the University of Waikato and an MBA from Hong Kong University.

### **About AbbVie**

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at [www.abbvie.com.au](http://www.abbvie.com.au). Follow @abbvie on [Twitter](#), [Facebook](#), [Instagram](#), [YouTube](#) and [LinkedIn](#).

**ENDS**

### **Media:**

Kate Richards

+61 466 420 739

[Kate.richards@abbvie.com](mailto:Kate.richards@abbvie.com)